Tuesday, October 11, 2016

Pristiq


Pristiq is a brand name of desvenlafaxine, approved by the FDA in the following formulation(s):


PRISTIQ (desvenlafaxine succinate - tablet, extended release; oral)



  • Manufacturer: WYETH PHARMS INC

    Approval date: February 29, 2008

    Strength(s): EQ 100MG BASE [RLD], EQ 50MG BASE [RLD]

Has a generic version of Pristiq been approved?


No. There is currently no therapeutically equivalent version of Pristiq available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pristiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Succinate salt of O-desmethyl-venlafaxine
    Patent 6,673,838
    Issued: January 6, 2004
    Inventor(s): Anthony F.; Hadfield & Syed M.; Shah & Michael W.; Winkley & Karen W.; Sutherland & James A.; Provost & Aeri; Park & Rex A.; Shipplett & Brenton W.; Russell & Beat T.; Weber
    Assignee(s): Wyeth
    A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Patent expiration dates:

    • February 11, 2022
      ✓ 
      Patent use: FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
      ✓ 
      Drug substance
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 1, 2013 - NEW CHEMICAL ENTITY

See also...

  • Pristiq Consumer Information (Drugs.com)
  • Pristiq Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Pristiq Consumer Information (Cerner Multum)
  • Pristiq Advanced Consumer Information (Micromedex)
  • Pristiq AHFS DI Monographs (ASHP)
  • Desvenlafaxine Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Desvenlafaxine Consumer Information (Cerner Multum)
  • Desvenlafaxine Advanced Consumer Information (Micromedex)
  • Desvenlafaxine Succinate AHFS DI Monographs (ASHP)

No comments:

Post a Comment